Printer Friendly Version in PDF Format (3 PDF pages)
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 81 - 90 of 165. 10 per page. Page 9.
Advanced SearchASPE Issue Brief
Assessing the Costs and Benefits of Extending Coverage of Immunosuppressive Drugs under Medicare
By statute, the majority of patients with end-stage renal disease (ESRD) are eligible for Medicare, regardless of age. Kidney transplantation is ultimately considered the best treatment for ESRD, but ESRD-related eligibility for Medicare coverage extends for only 36 months post-transplant.
Identifying Safety-Net Resources at Health Centers to Prevent Infectious Disease Transmission Resulting from the Opioid Epidemic
The impact of the opioid epidemic on infectious disease transmission is an important public health issue. The problem came dramatically to light in 2015 when an outbreak of new human immunodeficiency virus (HIV) infections occurred in rural Scott County, Indiana.
Using Evidence to Drive Decision-Making in Government
This report presents the findings from the Policy Analysis and Decision-Making Capacity project, funded by the Office of Science and Data Policy within the Office of the Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services.
ASPE Issue Brief
Expanding Access to Family-Centered Medication-Assisted Treatment Issue Brief
Printer Friendly Version in PDF Format (5 PDF pages)
State Policy Levers for Expanding Family-Centered Medication-Assisted Treatment
Printer Friendly Version in PDF Format (55 PDF pages)
Use of Medication-Assisted Treatment for Opioid Use Disorders in Employer-Sponsored Health Insurance: Out-of-Pocket Costs
This project assessed changes in opioid use disorder (OUD) treatment utilization and expenditures in the employer-sponsored private health insurance market during 2007 and 2014.
Use of Medication-Assisted Treatment for Opioid Use Disorders in Employer-Sponsored Health Insurance: Final Report
This project assessed changes in Opioid Use Disorder (OUD) treatment utilization and expenditures in the employer-sponsored private health insurance market at two timepoints, 2006-2007 and 2014-2015, that mark the periods before and after implementation of the Mental Health Parity and Addiction Equity Act (MHPAEA), the Affordable Care Act, the introduction and expanded use of new opioid treatme
Prescription Drug Pricing: ASPE Resources Related to Safe Harbor Rule
Department of Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson have issued a proposed rule, “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in
Medication-Assisted Treatment for Opioid Use Disorder in the Child Welfare Context: Challenges and Opportunities
This brief describes four key challenges related to the use of medication-assisted treatment (MAT) in child welfare contexts for parents with opioid use disorder. It draws upon results from a mixed methods study examining how substance use affects child welfare systems across the country. Key challenges discussed include: